Pharmaceutical major Ranbaxy Laboratories on Monday said its US-based subsidiary has launched Pravastatin Sodium tablets in 80mg strength in the US markets.
Being the first-to-file, the company would enjoy a 180- day exclusivity for Pravastatin, which is indicated in the treatment of primary prevention of coronary events without clinically evident heart disease.
"We will make Pravastatin Sodium 80 mg Tablets available to all classes of trade immediately," Ranbaxy Pharmaceuticals Inc (RPI) Vice President of Sales and Marketing Jim Meehan said in a communique to the Bombay Stock Exchange (BSE).
According to IMS MAT data for December 2006, the annual sales for Pravastatin-80mg were at 209 million dollar.
The drug is also useful in reducing risks of myocardial infarction, undergoing myocardial revascularisation procedures and cardiovascular mortality.
"We are delighted to have this product formulation as an addition to our ever expanding product portfolio of affordable generic alternatives," Meehan added.
Florida-based Ranbaxy Pharmaceuticals Inc (RPI) is a wholly-owned subsidiary of the country's largest pharmaceutical company. RPI is engaged in sale and distribution of generic and branded prescription products in the US healthcare system.
The shares of the domestic pharma major were last trading 0.86 per cent up at Rs 358.45 on the BSE.